US · HAE
Haemonetics Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Boston, MA 02110
- Website
- haemonetics.com
Price · as of 2025-03-29
$59.26
Market cap 2.96B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $63.01 | +6.33% |
| Intrinsic Value(DCF) | $30.18 | -49.07% |
| Graham-Dodd Method(GD) | $20.96 | -64.63% |
| Graham Formula(GF) | $39.83 | -32.78% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $32.39 | $55.43 | $1.88 | $19.35 | $20.29 |
| 2012 | $34.94 | $55.20 | $1.35 | $18.82 | $20.30 |
| 2013 | $40.27 | $113.05 | $10.75 | $12.32 | $22.48 |
| 2014 | $34.55 | $44.99 | $0.00 | $13.15 | $8.92 |
| 2015 | $42.50 | $50.60 | $0.00 | $11.18 | $1.73 |
| 2016 | $29.58 | $42.62 | $0.00 | $3.42 | $0.00 |
| 2017 | $41.37 | $41.12 | $0.00 | $7.72 | $0.00 |
| 2018 | $94.04 | $70.71 | $3.08 | $14.57 | $8.68 |
| 2019 | $103.72 | $86.39 | $1.46 | $14.21 | $15.83 |
| 2020 | $99.09 | $74.67 | $0.00 | $14.97 | $15.45 |
| 2021 | $60.07 | $58.44 | $0.72 | $13.07 | $0.00 |
| 2022 | $64.51 | $51.86 | $3.31 | $9.78 | $18.29 |
| 2023 | $88.14 | $77.08 | $1.30 | $18.29 | $56.73 |
| 2024 | $85.61 | $81.62 | $42.10 | $19.38 | $45.46 |
| 2025 | $70.46 | $63.01 | $32.08 | $20.96 | $39.83 |
AI valuation
Our deep-learning model estimates Haemonetics Corporation's (HAE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $63.01
- Current price
- $59.26
- AI upside
- +6.33%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$30.18
-49.07% upside
Graham-Dodd
$20.96
-64.63% upside
Graham Formula
$39.83
-32.78% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HAE | Haemonetics Corporation | $59.26 | 2.96B | +6% | -49% | -65% | -33% | 21.15 | 4.32 | 2.61 | 12.54 | 47.48 | -14.83 | 57.21% | 16.30% | 12.32% | 18.83% | 10.54% | 7.22% | 1.49 | 22.76 | 1.62 | 0.88 | 2.58 | 4454.00% | 395.00% | 2338.00% | 4.02% | 0.31 | 8.56% | 0.00% | 0.00% | 6.34% | 20.13 | 31.34 | 3.28 | 2.54 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| CON | Concentra Group Holdings … | $23.96 | 3.07B | +123% | -60% | — | +21% | 17.38 | 7.64 | 1.39 | 8.47 | — | -2.26 | 28.34% | 96.50% | 7.99% | 51.66% | 111.32% | 6.42% | 1.37 | 19.10 | 1.14 | 1.00 | 1.12 | 0.00% | 1385.00% | 3283.00% | 9.30% | 0.83 | 19.29% | 0.00% | 0.00% | 43.58% | 1.66 | 12.39 | 1.60 | 4.00 |
| CPRX | Catalyst Pharmaceuticals,… | $23.08 | 2.84B | +180% | +200% | -28% | +106% | 13.63 | 3.06 | 4.96 | 6.90 | 48.24 | 3.55 | 85.19% | 43.77% | 36.39% | 25.49% | 84.59% | 21.92% | 0.00 | — | 6.08 | 5.68 | -2.20 | 2824.00% | 1978.00% | -1281.00% | 7.14% | 1.42 | 90.56% | 0.00% | 0.00% | 7.46% | 8.59 | 10.61 | 3.76 | 14.42 |
| ITGR | Integer Holdings Corporat… | $86.68 | 3.04B | -17% | -60% | -62% | -46% | 29.17 | 1.72 | 1.62 | 14.64 | — | -15.81 | 26.99% | 12.93% | 5.55% | 6.11% | 6.77% | 3.17% | 0.80 | 5.55 | 3.32 | 1.57 | 4.62 | -1500.00% | 798.00% | 554.00% | 3.51% | 0.85 | 3.62% | 0.00% | 0.00% | 1.67% | 18.29 | 41.68 | 2.36 | 2.45 |
| LMAT | LeMaitre Vascular, Inc. | $108.18 | 2.45B | -46% | -51% | -89% | -62% | 41.10 | 5.37 | 8.23 | 25.41 | 93.35 | 7.69 | 68.63% | 23.77% | 20.03% | 13.87% | 18.60% | 9.80% | 0.55 | 254.91 | 13.14 | 10.77 | 2.40 | 4403.00% | 1363.00% | 2603.00% | 2.05% | 1.44 | 17.08% | 0.79% | 32.60% | 0.79% | 32.46 | 45.64 | 7.71 | 6.95 |
| PINC | Premier, Inc. | $28.26 | 2.34B | — | — | — | — | — | — | — | — | — | — | 73.41% | 0.11% | 2.00% | 3.56% | 0.04% | 1.91% | 0.18 | 0.06 | 0.64 | 0.55 | 0.85 | -7885.00% | -2479.00% | 4801.00% | — | 0.44 | 17.33% | — | 124.60% | — | — | — | — | — |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| WRBY | Warby Parker Inc. | $25.01 | 3.06B | +69% | -49% | -88% | -99% | 1965.26 | 8.77 | 3.70 | 59.48 | — | 8.77 | 53.97% | -0.61% | 0.19% | 0.46% | -0.92% | 0.23% | 0.63 | — | 2.35 | 1.93 | -1.00 | -10771.00% | 1304.00% | 2600.00% | 1.36% | 0.74 | 13.98% | 0.00% | 0.00% | 0.76% | -594.41 | 72.52 | 3.64 | 5.67 |
| XRAY | DENTSPLY SIRONA Inc. | $14.68 | 2.93B | +40% | -61% | — | — | -4.77 | 2.13 | 0.78 | -107.57 | — | -3.65 | 50.00% | 6.85% | -16.25% | -36.44% | 6.83% | -10.70% | 1.81 | 2.86 | 1.51 | 0.76 | -45.54 | -3304.00% | -298.00% | -6299.00% | 3.64% | 0.17 | 2.82% | 4.49% | -21.40% | 4.49% | 19.64 | 47.58 | 1.34 | 1.00 |
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
- CEO
- Christopher A. Simon
- Employees
- 3.66K
- Beta
- 0.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($30.18 ÷ $59.26) − 1 = -49.07% (DCF, example).